tiprankstipranks
Trending News
More News >
Procept Biorobotics Corp. (PRCT)
:PRCT
US Market
Advertisement

PROCEPT BioRobotics (PRCT) Stock Forecast & Price Target

Compare
481 Followers
See the Price Targets and Ratings of:

PRCT Analyst Ratings

Strong Buy
12Ratings
Strong Buy
9 Buy
3 Hold
0 Sell
Based on 12 analysts giving stock ratings to
PROCEPT
BioRobotics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRCT Stock 12 Month Forecast

Average Price Target

$77.00
▲(38.19%Upside)
Based on 12 Wall Street analysts offering 12 month price targets for PROCEPT BioRobotics in the last 3 months. The average price target is $77.00 with a high forecast of $85.00 and a low forecast of $68.00. The average price target represents a 38.19% change from the last price of $55.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","74":"$74","97":"$97","62.5":"$62.5","85.5":"$85.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,62.5,74,85.5,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.57,58.75692307692308,60.94384615384615,63.13076923076923,65.31769230769231,67.50461538461539,69.69153846153846,71.87846153846154,74.06538461538462,76.2523076923077,78.43923076923076,80.62615384615384,82.81307692307692,{"y":85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.57,58.14153846153846,59.713076923076926,61.284615384615385,62.856153846153845,64.42769230769231,65.99923076923076,67.57076923076923,69.1423076923077,70.71384615384615,72.28538461538461,73.85692307692308,75.42846153846153,{"y":77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.57,57.449230769230766,58.32846153846154,59.207692307692305,60.08692307692308,60.966153846153844,61.84538461538462,62.72461538461538,63.603846153846156,64.48307692307692,65.3623076923077,66.24153846153847,67.12076923076923,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.87,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$85.00Average Price Target$77.00Lowest Price Target$68.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PRCT
TipRanks AITipRanks
Not Ranked
TipRanks
$57
Hold
2.30%
Upside
Reiterated
07/26/25
PROCEPT BioRobotics demonstrates robust revenue growth and a strong equity position, which are promising for long-term stability. However, persistent operating losses, negative cash flows, and challenging valuation metrics weigh heavily on the score. Recent strategic advancements and a positive corporate event provide some optimism, but the overall outlook remains cautious due to financial and market momentum challenges.
Truist Financial Analyst forecast on PRCT
Richard NewitterTruist Financial
Truist Financial
Buy
Reiterated
07/25/25
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT) and Bausch Health Companies (NYSE: BHC)
Oppenheimer Analyst forecast on PRCT
Suraj KaliaOppenheimer
Oppenheimer
Hold
Reiterated
07/25/25
Oppenheimer Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)Oppenheimer analyst Suraj Kalia reiterated a Perform rating and {REMOVEPT} price target on Procept BioRobotics Corp (NASDAQ: PRCT)
TD Cowen
$85
Buy
52.55%
Upside
Reiterated
07/25/25
TD Cowen Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
BTIG
Hold
Reiterated
07/25/25
BTIG Sticks to Their Hold Rating for PROCEPT BioRobotics (PRCT)
William Blair Analyst forecast on PRCT
Brandon VazquezWilliam Blair
William Blair
Buy
Reiterated
07/24/25
PROCEPT BioRobotics: Promising Growth Under New Leadership and Attractive Valuation
Leerink Partners Analyst forecast on PRCT
Mike KratkyLeerink Partners
Leerink Partners
Buy
Reiterated
07/16/25
Leerink sees positive readthrough for Procept after CMS' OPPS proposed ruleLeerink sees positive readthrough for Procept after CMS' OPPS proposed rule
Bank of America Securities Analyst forecast on PRCT
Craig BijouBank of America Securities
Bank of America Securities
$84
Buy
50.75%
Upside
Reiterated
07/15/25
Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation
Morgan Stanley Analyst forecast on PRCT
Patrick WoodMorgan Stanley
Morgan Stanley
$71$68
Buy
22.04%
Upside
Reiterated
07/15/25
Procept BioRobotics price target lowered to $68 from $71 at Morgan StanleyProcept BioRobotics price target lowered to $68 from $71 at Morgan Stanley
Wells Fargo Analyst forecast on PRCT
Nathan TreybeckWells Fargo
Wells Fargo
$105$75
Buy
34.60%
Upside
Assigned
07/14/25
Wells Fargo Keeps Their Buy Rating on PROCEPT BioRobotics (PRCT)
Stephens
$70
Buy
25.63%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Piper Sandler Analyst forecast on PRCT
Matthew O'BrienPiper Sandler
Piper Sandler
$100$80
Buy
43.58%
Upside
Reiterated
04/28/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (NASDAQ: CTKB), Esperion (NASDAQ: ESPR) and PROCEPT BioRobotics (NASDAQ: PRCT)
TD Securities Analyst forecast on PRCT
Unknown AnalystTD Securities
Not Ranked
TD Securities
$99$85
Buy
52.55%
Upside
Reiterated
02/26/25
Lowering PT to $85 from $99.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PRCT
TipRanks AITipRanks
Not Ranked
TipRanks
$57
Hold
2.30%
Upside
Reiterated
07/26/25
PROCEPT BioRobotics demonstrates robust revenue growth and a strong equity position, which are promising for long-term stability. However, persistent operating losses, negative cash flows, and challenging valuation metrics weigh heavily on the score. Recent strategic advancements and a positive corporate event provide some optimism, but the overall outlook remains cautious due to financial and market momentum challenges.
Truist Financial Analyst forecast on PRCT
Richard NewitterTruist Financial
Truist Financial
Buy
Reiterated
07/25/25
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT) and Bausch Health Companies (NYSE: BHC)
Oppenheimer Analyst forecast on PRCT
Suraj KaliaOppenheimer
Oppenheimer
Hold
Reiterated
07/25/25
Oppenheimer Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)Oppenheimer analyst Suraj Kalia reiterated a Perform rating and {REMOVEPT} price target on Procept BioRobotics Corp (NASDAQ: PRCT)
TD Cowen
$85
Buy
52.55%
Upside
Reiterated
07/25/25
TD Cowen Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
BTIG
Hold
Reiterated
07/25/25
BTIG Sticks to Their Hold Rating for PROCEPT BioRobotics (PRCT)
William Blair Analyst forecast on PRCT
Brandon VazquezWilliam Blair
William Blair
Buy
Reiterated
07/24/25
PROCEPT BioRobotics: Promising Growth Under New Leadership and Attractive Valuation
Leerink Partners Analyst forecast on PRCT
Mike KratkyLeerink Partners
Leerink Partners
Buy
Reiterated
07/16/25
Leerink sees positive readthrough for Procept after CMS' OPPS proposed ruleLeerink sees positive readthrough for Procept after CMS' OPPS proposed rule
Bank of America Securities Analyst forecast on PRCT
Craig BijouBank of America Securities
Bank of America Securities
$84
Buy
50.75%
Upside
Reiterated
07/15/25
Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation
Morgan Stanley Analyst forecast on PRCT
Patrick WoodMorgan Stanley
Morgan Stanley
$71$68
Buy
22.04%
Upside
Reiterated
07/15/25
Procept BioRobotics price target lowered to $68 from $71 at Morgan StanleyProcept BioRobotics price target lowered to $68 from $71 at Morgan Stanley
Wells Fargo Analyst forecast on PRCT
Nathan TreybeckWells Fargo
Wells Fargo
$105$75
Buy
34.60%
Upside
Assigned
07/14/25
Wells Fargo Keeps Their Buy Rating on PROCEPT BioRobotics (PRCT)
Stephens
$70
Buy
25.63%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Piper Sandler Analyst forecast on PRCT
Matthew O'BrienPiper Sandler
Piper Sandler
$100$80
Buy
43.58%
Upside
Reiterated
04/28/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (NASDAQ: CTKB), Esperion (NASDAQ: ESPR) and PROCEPT BioRobotics (NASDAQ: PRCT)
TD Securities Analyst forecast on PRCT
Unknown AnalystTD Securities
Not Ranked
TD Securities
$99$85
Buy
52.55%
Upside
Reiterated
02/26/25
Lowering PT to $85 from $99.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PROCEPT BioRobotics

1 Month
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+6.28%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +6.28% per trade.
3 Months
xxx
Success Rate
11/13 ratings generated profit
85%
Average Return
+21.47%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +21.47% per trade.
1 Year
Craig BijouBank of America Securities
Success Rate
11/13 ratings generated profit
85%
Average Return
+37.45%
reiterated a buy rating 13 days ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +37.45% per trade.
2 Years
xxx
Success Rate
11/13 ratings generated profit
85%
Average Return
+37.05%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +37.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRCT Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
2
7
5
5
1
Buy
11
15
9
11
14
Hold
4
5
6
9
17
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
27
20
25
32
In the current month, PRCT has received 15 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. PRCT average Analyst price target in the past 3 months is 77.00.
Each month's total comprises the sum of three months' worth of ratings.

PRCT Financial Forecast

PRCT Earnings Forecast

Next quarter’s earnings estimate for PRCT is -$0.42 with a range of -$0.49 to -$0.31. The previous quarter’s EPS was -$0.45. PRCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.93% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.
Next quarter’s earnings estimate for PRCT is -$0.42 with a range of -$0.49 to -$0.31. The previous quarter’s EPS was -$0.45. PRCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.93% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.

PRCT Sales Forecast

Next quarter’s sales forecast for PRCT is $76.71M with a range of $72.33M to $79.20M. The previous quarter’s sales results were $69.16M. PRCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.41% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.
Next quarter’s sales forecast for PRCT is $76.71M with a range of $72.33M to $79.20M. The previous quarter’s sales results were $69.16M. PRCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.41% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.

PRCT Stock Forecast FAQ

What is PRCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Procept Biorobotics Corp.’s 12-month average price target is 77.00.
    What is PRCT’s upside potential, based on the analysts’ average price target?
    Procept Biorobotics Corp. has 38.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRCT a Buy, Sell or Hold?
          Procept Biorobotics Corp. has a consensus rating of Strong Buy which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Procept Biorobotics Corp.’s price target?
            The average price target for Procept Biorobotics Corp. is 77.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $85.00 ,the lowest forecast is $68.00. The average price target represents 38.19% Increase from the current price of $55.72.
              What do analysts say about Procept Biorobotics Corp.?
              Procept Biorobotics Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of PRCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis